ISPOR Releases Top 10 HEOR Trends Report for 2022-2023

By HEOR Staff Writer

January 17, 2023

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a renowned professional society in Health Economics and Outcomes Research (HEOR). Biennially, it publishes a report, outlining the ISPOR Top 10 HEOR Trends. This article explores the 2022-2023 top trends, heavily influenced by the COVID-19 pandemic, and their implications for the healthcare industry.

Real-world Evidence (RWE) – The Number One Trend

RWE has been identified as the top trend for 2022-2023. Its significance has grown due to its crucial role in addressing the pandemic. Health data, which is integral to RWE, also joins the trends list at number nine.

Health Equity – A New Entrant in the Top Trends

The pandemic has starkly highlighted health disparities and their devastating impact. As a result, health equity has emerged as a top trend, ranking third on the list.

Public Health and Health Technology Assessment (HTA) – Rising Trends

Public health has also been elevated in the trends list, ranking seventh, no doubt due to the pandemic’s impact. HTA enters the list at number eight, underlining the importance of evaluating healthcare interventions.

Artificial Intelligence – A Key Player in the Top Trends

Artificial Intelligence (AI) has made its mark, joining the top trends at number ten. It’s clear that healthcare data and AI are becoming increasingly intertwined, driving innovation and efficiency in the sector.


These top trends in HEOR provide valuable insights for all healthcare stakeholders, from researchers and academicians to life sciences industry professionals and patients. They highlight the importance of informed health decisions backed by rigorous, proven methodologies.

 

Reference url

Recent Posts

Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards

By João L. Carapinha

January 7, 2026

Aligning U.S. Childhood Immunization Schedules with International Benchmarks Recent childhood immunization reforms by the U.S. Centers for Disease Control and Prevention (CDC) follow a presidential directive...
Novartis Drug Pricing Agreement
Novartis reached a drug pricing agreement with the US government that lowers prices for innovative medicines, while the firm will launch future drugs at comparable prices across high-income countries. Novartis also introduces direct-to-patient platforms for Mayzent, Rydapt, and Tabrecta via Trump...
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity

By João L. Carapinha

January 6, 2026

Recent mRNA vaccine advancements are poised to transform global health by expanding beyond COVID-19 to tackle neglected infectious diseases and even therapeutic uses. Experts forecasting breakthroughs for 2026 highlight how these innovations use lipid nanoparticles to deliver RNA sequences encodi...